Table 3.
Predictors of Failure of Hemodynamic Optimization at Set LVAD Speed Among Baseline Characteristics
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | |
| Age, y | 1.00 (0.96–1.04) | 0.97 | ||
| Sex, male | 1.34 (0.56–3.22) | 0.51 | ||
| Race, white | 1.21 (0.70–2.08) | 0.50 | ||
| Body mass index | 0.98 (0.93–1.04) | 0.53 | ||
| Preramp LVAD duration, d | 1.00 (1.00–1.00) | 0.35 | ||
| Nonischemic cardiomyopathy | 2.99 (1.18–7.58) | 0.02* | ||
| Destination therapy | 3.45 (1.05–11.3) | 0.04* | ||
| HeartMate II device | 2.06 (0.81–5.24) | 0.13 | ||
| Hypertension | 0.69 (0.29–1.63) | 0.40 | ||
| Diabetes mellitus | 1.24 (0.52–2.96) | 0.63 | ||
| History of stroke | 1.44 (0.44–4.71) | 0.55 | ||
| Atrial fibrillation | 2.67 (1.10–6.52) | 0.031* | ||
| History of ventricular tachyarrhythmias | 1.80 (0.63–5.12) | 0.27 | ||
| CVP at baseline speed, mm Hg | 1.02 (0.96–1.09) | 0.48 | ||
| PCWP at baseline speed, mm Hg | 1.00 (0.96–1.05) | 0.90 | ||
| Cardiac index at baseline speed, L/(min·m2) | 1.00 (0.51–1.97) | 0.99 | ||
| PAPi at baseline speed | 0.68 (0.50–0.92) | 0.014* | 0.68 (0.50–0.92) | 0.014* |
| Hemoglobin, g/dL | 1.11 (0.86–1.43) | 0.43 | ||
| Hematocrit, % | 1.05 (0.95–1.15) | 0.37 | ||
| eGFR, mL/(min·1.73 m2) | 0.99 (0.97–1.01) | 0.99 | ||
| Serum total bilirubin, mg/dL | 0.81 (0.40–1.63) | 0.56 | ||
| Preramp total admission, events/y | 1.04 (0.82–1.33) | 0.74 | ||
| Preramp HF admission, events/y | 0.77 (0.30–1.99) | 0.59 | ||
| Preramp non-HF admission, events/y | 1.07 (0.83–1.40) | 0.60 | ||
CVP indicates central venous pressure; eGFR, estimated glomerular filtration ratio; HF, heart failure; LVAD, left ventricular assist device; OR, odds ratio; PAPi, pulmonary artery pressure index; and PCWP, pulmonary capillary wedge pressure.
*
P<0.05 by logistic regression analyses.